Induction of immunity to antigens expressed by recombinant adeno- associated virus depends on the route of administration

Clinical Immunology

Volumn 92, Issue 1, 1999, Pages 67-75

  Brockstedt, Dirk G ^a,b   Podsakoff, Greg M ^c   Fong, Lawrence ^a   Kurtzman, Gary ^c   Mueller Ruchholtz, Wolfgang ^b   Engleman, Edgar G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c Avigen Inc   (United States)

Author keywords

Adeno associated virus; Cytotoxic T lymphocytes; Ovalbumin

Indexed keywords

OVALBUMIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

EID: 0032977833     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4724     Document Type: Article

References (30)

1. Tuting T., Storkus W. J., Lotze M. T. Gene-based strategies for the immunotherapy of cancer. J. Mol. Med. 75:1997;478-491.
2. McCabe B. J., Irvine K. R., Nishimura M. I., Yang J. C., Spiess P. J., Shulman E. P., Rosenberg S. A., Restifo N. P. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. 55:1995;1741-1747.
3. Roth J., Dittmer D., Rea D., Tartaglia J., Paoletti E., Levine A. J. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl. Acad. Sci. USA. 93:1996;4781-4786.
4. Lee C. T., Wu S., Ciernik I. F., Chen H., Nadaf-Rahrov S., Gabrilovich D., Carbone D. P. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. 8:1997;187-193.
5. Katsumi A., Emi N., Abe A., Hasegawa Y., Ito M., Saito H. Humoral and cellular immunity to an encoded protein induced by direct DNA injection. Hum. Gene Ther. 5:1994;1335-1339.
6. Ballard J. D., Collier R. J., Starnbach M. N. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;12531-12534.
7. Berns K. I., Bohenzky R. A. Adeno-associated viruses: An update. Adv. Virus Res. 32:1987;243-306.
8. Fisher K. J., Jooss K., Alston J., Yang Y., Haecker S. E., High K., Pathak R., Raper S. E., Wilson J. M. Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3:1997;306-312.
9. Flotte T. R., Afione S. A., Conrad C., McGrath S. A., Solow R., Oka H., Zeitlin P. L., Guggino W. B., Carter B. J. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. USA. 90:1993;10613-10617.
10. Kessler P. D., Podsakoff G. M., Chen X., McQuiston S. A., Colosi P. C., Matelis L. A., Kurtzman G. J., Byrne B. J. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA. 93:1996;14082-14087.
11. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158:1992;97-129.
12. Kotin R. M. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum. Gene Ther. 5:1994;793-801.
13. Xiao X., Li J., Samulski R. J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70:1996;8098-8108.
14. Manning W. C., Paliard X., Zhou S., Pat Bland M., Lee A. Y., Hong K., Walker C. M., Escobedo J. A., Dwarki V. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J. Virol. 71:1997;7960-7962.
15. Hurpin C., Rotarioa C., Bisceglia H., Chevalier M., Tartaglia J., Erdile L. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine. 16:1998;208-215.
16. Yokoyama M., Hassett D. E., Zhang J., Whitton J. L. DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site. Vaccine. 15:1997;553-560.
17. Andrew M. E., Coupar B. E., Boyle D. B. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immunol. Cell Biol. 67:1989;331-337.
18. Song W., Kong H. L., Traktman P., Crystal R. G. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum. Gene Ther. 8:1997;1207-1217.
19. Colosi P., Elliger S., Elliger C., Kurtzman G. J. AAV vectors can be efficiently produced without helper virus. Blood. 86:1995;627a.
20. Takada S., Koide J., Engleman E. G. Differences in surface phenotype between cytolytic and non-cytolytic CD4+ T cells. J. Immunol. 142:1989;3038-3044.
21. Falo L. D. Jr., Kovacsovics-Bankowski M., Thompson K., Rock K. L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1:1995;649-653.
22. Condon C., Watkins S. C., Celluzzi C. M., Thompson K., Falo L. D. Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1996;1122-1128.
23. Monaco J. J. A molecular model of MHC class-I-restricted antigen processing. Immunol. Today. 13:1992;173-178.
24. Rock K. L. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today. 17:1995;131-137.
25. Karttunen J., Sanderson S., Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. USA. 89:1992;6020-6024.
26. Attaya M., Jameson S., Martinez C. K., Hermel E., Aldrich C., Forman J., Lindahl K. F., Bevan M. J., Monaco J. J. Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature. 355:1992;647-649.
27. Chiorini J. A., Yang L., Liu Y., Safer B., Kotin R. M. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71:1997;6823-6833.
28. Halbert C. L., Standaert T. A., Aitken M. L., Alexander I. E., Russell D. W., Miller A. D. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J. Virol. 71:1997;5932-5941.
29. Manning W. C., Zhou S., Bland M. P., Escobedo J. A., Dwarki V. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9:1998;477-485.
30. Iezzi G., Karjalainen K., Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 8:1998;89-95.